Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | glucosylceramidase, putative | 0.5659 | 1 | 1 |
Loa Loa (eye worm) | O-glycosyl hydrolase family 30 protein | 0.5659 | 1 | 1 |
Brugia malayi | Ceramide glucosyltransferase | 0.5227 | 0.8897 | 0.8592 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.5659 | 1 | 1 |
Echinococcus granulosus | non lysosomal glucosylceramidase | 0.4561 | 0.7197 | 0.7473 |
Echinococcus multilocularis | non lysosomal glucosylceramidase | 0.4561 | 0.7197 | 0.7473 |
Echinococcus granulosus | bile acid beta glucosidase | 0.4561 | 0.7197 | 0.7473 |
Echinococcus multilocularis | ceramide glucosyltransferase | 0.5227 | 0.8897 | 1 |
Schistosoma mansoni | ceramide glucosyltransferase | 0.5227 | 0.8897 | 1 |
Loa Loa (eye worm) | ceramide glucosyltransferase | 0.5227 | 0.8897 | 0.8592 |
Echinococcus multilocularis | bile acid beta glucosidase | 0.4561 | 0.7197 | 0.7473 |
Schistosoma mansoni | bile acid beta-glucosidase-related | 0.4561 | 0.7197 | 0.7473 |
Onchocerca volvulus | Glucosylceramidase homolog | 0.3713 | 0.5033 | 0.5657 |
Onchocerca volvulus | Ceramide glucosyltransferase homolog | 0.5227 | 0.8897 | 1 |
Echinococcus granulosus | ceramide glucosyltransferase | 0.5227 | 0.8897 | 1 |
Giardia lamblia | Ceramide glucosyltransferase | 0.237 | 0.1604 | 0.5 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.5659 | 1 | 1 |
Schistosoma mansoni | bile acid beta-glucosidase-related | 0.4561 | 0.7197 | 0.7473 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.5659 | 1 | 1 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.3913 | 0.5543 | 0.1027 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.3913 | 0.5543 | 0.1027 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.5659 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.3079 | 0.3414 | 0.1588 |
Schistosoma mansoni | ceramide glucosyltransferase | 0.5227 | 0.8897 | 1 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.5659 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.